- Date 28 Sep 2020
Nuformix a pharmaceutical development company focused on unlocking the therapeutic potential and value of known
drugs to develop novel medicines to provide enhanced benefit, announces it has signed an exclusive
option agreement with Oxilio Ltd (“Oxilio”)
You might also be interested in these articles
Hawkins launches new acoustics consultancy website
Mon 26 Oct 2020
Hawkins & Associates Ltd
Ricardo commits to public and verifiable environmental performance pledges
Mon 26 Oct 2020
Ricardo UK Ltd
BT and Toshiba install UK’s first quantum-secure industrial network between key UK smart production facilities
Mon 26 Oct 2020
Toshiba Research Europe Ltd
